<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025698</url>
  </required_header>
  <id_info>
    <org_study_id>CETB115E2201</org_study_id>
    <nct_id>NCT03025698</nct_id>
  </id_info>
  <brief_title>A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia</brief_title>
  <official_title>A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open label, multi-center, intra-patient dose escalation study to
      characterize the pharmacokinetics after oral administration of eltrombopag in combination
      with immunosuppressive therapy in pediatric patients with previously untreated or
      relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.

      All patients will be treated with eltrombopag for the 26-week Treatment Period, followed by a
      52-week Follow-Up Period. Patients who have been previously untreated with immunosuppressive
      therapy will be treated according to the standard of care, hATG/cyclosporine, in addition to
      eltrombopag. Patients with relapsed/refractory SAA or recurrent AA will be enrolled into one
      of two treatment options: hATG/cyclosporine plus eltrombopag or cyclosporine plus
      eltrombopag, depending on prior treatment with immunosuppressive therapy.

      After initiating treatment with eltrombopag, patients will have their dose assessed and
      modified as tolerated, until the targeted platelet count or maximum dose is achieved.
      Pharmacokinetic assessments will be performed at time points intended to capture steady state
      PK of the starting dose and highest dose achieved.

      Upon completion of the Treatment and Follow-Up Periods, all patients will be offered the
      opportunity to enroll in an additional 3 year Long Term Follow-Up Period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2017</start_date>
  <completion_date type="Anticipated">March 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: AUCtau</measure>
    <time_frame>2 weeks and 12 weeks after dose initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: Cmax</measure>
    <time_frame>2 weeks and 12 weeks after dose initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: Ctrough</measure>
    <time_frame>2 weeks and 12 weeks after dose initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an overall response (OR)</measure>
    <time_frame>Week 12, Week 26, Week 52, and Week 78.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a platelet response.</measure>
    <time_frame>Week 12, Week 26, Week 52, and Week 78.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clonal chromosomal population in bone marrow, myelodysplasia by morphology or acute leukemia</measure>
    <time_frame>Week 12, Week 26, Week 52 and Week 78.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Tablet for oral use, once daily</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hATG</intervention_name>
    <description>Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <description>Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For Cohort A:

          1. Prior history of diagnosis of SAA

          2. Diagnosis of relapsed/refractory SAA or recurrent AA following IST for SAA at the time
             of enrollment. Patients with recurrent AA (e.g., losing their response) are exempt
             from meeting the diagnostic criteria for relapsed SAA at the time of enrollment, but
             must have been previously diagnosed with SAA.

          3. Agree to concurrent eltrombopag treatment with appropriate, investigator-selected IST
             with either hATG + CsA or CsA.

             For Cohort B:

          4. Diagnosis of SAA at the time of enrollment

          5. Patients must not have been previously treated for SAA

          6. Patients must agree to treatment with hATG + CsA concurrent with eltrombopag.

             For all patients, regardless of cohort:

          7. Age 1 to &lt;18 years

          8. Where appropriate, assessments to rule out congenital/inherited bone marrow failure
             syndromes and other causes of immune-mediated pancytopenia, which may be treated with
             transplant, must be completed prior to enrollment.

          9. Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a
             treatment option or has been refused by the patient. (Candidacy for HSCT will be
             determined as per local practice.)

         10. Bone marrow aspirate and biopsy at any time during the 4 weeks prior to first dose of
             eltrombopag

         11. Normal karyotype with FISH for chromosomes 7 and 8

         12. Performance status score: Karnofsky ≥50 or Lansky ≥50 (depending on age)

         13. Serum creatinine ≤2.5 × ULN

         14. Total bilirubin ≤1.5 × ULN

         15. Written informed consent signed by a parent or legal guardian prior to initiation of
             any study specific procedure.

        Exclusion Criteria:

          1. Prior and/or active medical history of:

               -  Fanconi anemia (via chromosomal breakage test or growth arrest by flow cytometry)

               -  Other known underlying congenital/inherited marrow failure syndromes

               -  Symptomatic Paroxysmal Nocturnal Hemoglobinuria (PNH) and/or PNH clones &gt;50% of
                  PMN or RBC at time of enrollment

               -  Any cytogenetic abnormalities, including but not limited to chromosome 7 or
                  myelodysplasia, in bone marrow within 4 weeks of study enrollment

               -  Myelodysplastic syndrome (MDS)

               -  Other known or suspected underlying primary immunodeficiency

               -  Any malignancy

          2. Active infection not responding to appropriate therapy

          3. Prior eltrombopag or other thrombopoietin receptor (TPO-R) agonist treatment for at
             least 2 months and a lack of response.

          4. Any out of range lab values Creatinine &gt;2.5 × upper limit of normal (ULN), Total
             bilirubin &gt;1.5 × ULN Aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT) &gt;2.5 × ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital SC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzy Hall</last_name>
      <phone>501-364-4181</phone>
      <email>Hallsf@ARchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jason Farrar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Moore</last_name>
      <phone>720-777-6353</phone>
      <email>Wendy.moore2@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Taizo Nakano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Childrens Hospital of Chicago SC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trecia Dawkins</last_name>
      <phone>312-227-4825</phone>
      <email>TMalcolm@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Alexis Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University SC Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Bubnick</last_name>
      <email>abubnick@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Grzegorz Nalepa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Boston SC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Malsch</last_name>
      <phone>617-355-4685</phone>
      <email>Maggie.Malsch@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Akiko Shimamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center SC-2</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Haugh</last_name>
      <phone>551-996-3457</phone>
      <email>Jeanette.Haugh@Hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Alfred Gillio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital Drug Shipment</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sini Sreenivas</last_name>
      <phone>206-987-4329</phone>
      <email>sini.sreenivas@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Amy Geddis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>March 3, 2018</last_update_submitted>
  <last_update_submitted_qc>March 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eltrombopag</keyword>
  <keyword>hATG</keyword>
  <keyword>CsA</keyword>
  <keyword>previously untreated or relapsed severe aplastic anemia</keyword>
  <keyword>recurrent aplastic anemia</keyword>
  <keyword>Severe aplastic anemia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunosuppressive therapy</keyword>
  <keyword>ETB115</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

